BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Generous AstraZeneca PLC (AZN) Provided More Than Half A Million Patients With Free Medicine In 2013


2/21/2014 8:11:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Patient Assistance Programs Provided More Than Half a Million Patients with Free Medicine in 2013

WILMINGTON, Del.--(BUSINESS WIRE)--February 20, 2014-- AstraZeneca (NYSE:AZN) announced today that, in 2013, it provided nearly $975 million in savings to more than 567,000 patients in the United States through its patient assistance programs. These programs include AZ&Me and the MedImmune Assistance Program.

"At AstraZeneca, we work hard to understand the needs of patients, and we're committed to helping them afford their medications," said Paul Hudson, President, AstraZeneca U.S. and Executive Vice President, North America. "For more than 35 years, our patient assistance programs have been helping people access the medicines they need, and we look forward to bringing them continued savings and benefits in 2014."

AstraZeneca's AZ&Me prescription savings programs are designed to help qualifying people without insurance, those in Medicare Part D, those who receive their medications through participating health care facilities, and those who have faced a financial challenge recently.

-- Individuals without Prescription Drug Coverage: AstraZeneca provides free medicines to qualifying individuals with an annual income at or below $35,000 and families of four with an annual household income at or below $70,000.

-- Part D Beneficiaries: AstraZeneca provides free medicines to qualifying Medicare Part D beneficiaries with an annual income at or below $35,000 and couples with an annual household income at or below $48,000.

-- Healthcare Facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program helps provide medicines to qualifying patients at the time and place of treatment.

The MedImmune Assistance Program provides medication free of charge to qualified patients who are uninsured, or who have been rendered uninsured by their insurance company. Qualified patients must meet all eligibility criteria.

Click here for a visual overview of AstraZeneca's prescriptions savings programs. For more detailed information about the AZ&Me prescription savings programs, please visit www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). For additional information about the MedImmune Assistance Program, visit www.myAccess360.com or call 1-877-778-9010.

AstraZeneca also participates in multi-manufacturer programs like the Partnership for Prescription Assistance and supports other organizations with the same goal--increasing access to medicines as well as health care.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140220005341/en/

CONTACT: Media Inquiries:

AstraZeneca
Michele Meixell, 302-885-2677
Michele.Meixell@AstraZeneca.com
or
Alisha Martin, 302-885-2677
Alisha.Martin@AstraZeneca.com

SOURCE: AstraZeneca

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES